Evaluation of bioequivalence of two tablet forms of lisinopril in healthy volunteers
Under cross, single, open, randomized trial with 1 week washout period, with two sequences of 18 volunteers studied bioequivalence coated tablets, two manufacturers of lisinopril (20 mg dose).
S. A. Altynbekov +5 more
doaj
Safety and tolerability of the ACE-inhibitor lisinopril among Nigerian adults with HIV: preliminary pilot data from a randomized clinical trial. [PDF]
Dankishiya FS +13 more
europepmc +1 more source
Lisinopril is drug choice for hypertension therapy that works by inhibiting the action of angiotensin-converting enzyme (ACE). In 2011, research about the effect of circadian rhythms on the renin-angiotensin system proves that the main target of anti ...
, Annisa Nadya Utami +1 more
core
Lisinopril tabletták hatóanyagtartalom meghatározási módszerének fejlesztése és validálása
Lisinopril tabletták hatóanyagtartalom meghatározási módszerének fejlesztése és validálása.gjvegyészmérnök (gyógyszeripari specializáció)MSc ...
Hartman, Éva Tünde
core
Lisinopril activates BI1 to reprogram lipid metabolism and restore autophagy in ALS. [PDF]
Yin H +8 more
europepmc +1 more source
Diagnosis of Lisinopril-Induced Small Bowel Angioedema After a Seven-Year Diagnostic Journey: A Case Report With Patient Perspective. [PDF]
Sutton S, Paulson J.
europepmc +1 more source
Adverse event of ACE inhibitors: A descriptive analysis of FAERS data. [PDF]
Ahmed NJ.
europepmc +1 more source
Angioedema After Accidental Semaglutide Dosing Error: A Case Report. [PDF]
Kraft BD, Matuszak S.
europepmc +1 more source
Angiotensin-converting enzyme (ACE) inhibition with captopril is accepted therapy for the treatment of symptomatic congestive heart failure. In this trial, we compared the new ACE inhibitor, lisinopril, to captopril during a 12-week randomized double ...
Powers, E. R. +9 more
core
ACE inhibitor-induced bradykinin-mediated angioedema presenting as small bowel obstruction and life-threatening airway angioedema: a rare dual presentation. [PDF]
Ghimire P, Sathya DA, Tang A, Yaqoob H.
europepmc +1 more source

